Intelligent Bio Solutions (INBS) announced an update on its growing footprint in the U.S. Forensic Use Only Market through its strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services. SMARTOX supports clients across corrections, drug courts, rehabilitation centres, and other forensic environments. It has deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone, highlighting accelerated demand for non-invasive, rapid testing in forensic settings. INBS’ drug screening technology is credited with reducing reliance on invasive methods such as urine or saliva collection, while delivering rapid and reliable results directly linked to the individual tested.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio Solutions (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25
- Intelligent Bio Solutions (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows
- Intelligent Bio Solutions (NASDAQ: INBS) to Showcase Fingerprint Drug Testing at RISE25 Conference
- Intelligent Bio Solutions to showcase fingerprint drug testing at RISE25
- Intelligent Bio announces completion of high-volume workforce drug test